The biggest item this week: FDA sent a warning letter to an IV hydration company over its stem cell and exosome drips, and addressed it to the company’s Medical Director. If your IV menu lists either product, read item 1 first.
Covers October 23 to 29, 2026. Every item links to the agency document it comes from.
1. FDA says stem cell and exosome IV drips are unapproved drugs and unlicensed biologics
On October 13, 2026, FDA’s biologics center issued a warning letter to Calibrate IV Hydration (CBER 26-729846). FDA posted it on October 27. The letter is addressed to the company’s Medical Director. FDA reviewed the company’s website and found umbilical cord-derived and exosome products sold as a “Stem Cell IV,” an “Exosome IV” and combination packages.
FDA found the products are drugs under section 201(g)(1) of the FD&C Act with no approved application, and biological products with no license under section 351(a)(1) of the PHS Act. It found the cord product fails the homologous use criterion in 21 CFR 1271.10(a)(2) and qualifies for no exception in 21 CFR 1271.15. FDA quoted the website’s claims about brain health, joint, muscle and bone health, and “managing inflammation.” A footnote points to FDA’s public safety notification on exosome products after reports of serious adverse events. The company has 15 working days to respond.
What to do: if your menu lists a stem cell or exosome drip, have your medical director pull it and review every claim on your site against this letter. Stem cell and exosome marketing.
Source: FDA warning letter 729846
2. DEA revokes two registrations because the state license is gone
On October 26, 2026, DEA published two decisions and orders, each effective November 25, 2026. In FR Doc. 2026-21799, DEA revoked the registration of a Washington physician whose state license had been suspended on January 23, 2026 after the Department of Health found unprofessional conduct. In FR Doc. 2026-21725, DEA revoked the registration of an Ohio dentist whose state license expired on December 31, 2023. He did not request a hearing, so the allegations were deemed admitted.
Both orders rest on 21 U.S.C. 824(a)(3) and 21 U.S.C. 823(g)(1). A practitioner who is not authorized to prescribe or dispense controlled substances in the state of registration cannot hold a DEA registration there. DEA cited Wash. Rev. Code § 69.50.308(j) and Ohio Rev. Code § 2925.11. The Ohio order shows a license can lapse for years while the registration stays active.
What to do: if a physician or provider in your network prescribes testosterone or other controlled substances, verify each state license and each DEA registration on a set schedule, and write down the date you checked. Your personal license is the collateral.
Sources: FR Doc. 2026-21799 and FR Doc. 2026-21725.
3. An overseas seller of placenta and “embryonic stem cell” products gets the same finding
On September 25, 2026, FDA’s biologics center issued a warning letter to Beaute Bounty, a Malaysia-based online seller (CBER 26-729163), posted October 27. The products were Evgenis Totipotent Embryonic Stem Cells, Laennec and Melsmon Placenta Japan. FDA found each is an unapproved new drug and an unlicensed biological product, and that none meets the homologous use criterion in 21 CFR 1271.10(a)(2). It quoted claims such as “Reduce pain, even chronic joint pain, with less need for medications” and “Prevent the hardening of liver.” The company has 15 working days to respond.
What to do: if a supplier offers placenta-derived or “stem cell” injectables for mesotherapy or IV use, ask for the approved application or license. If the supplier cannot name one, do not administer the product. Aesthetics and injectables oversight.
Source: FDA warning letter 729163
4. FDA objects to marketing a cleared muscle stimulator for menstrual pain
On October 2, 2026, FDA’s device center issued a warning letter to Chirp Innovations, LLC (CMS #731847), posted October 27. The company’s over-the-counter TENS and EMS unit was cleared under K241509 for temporary relief of sore muscles and for stimulating healthy muscles. FDA says promoting it for menstrual pain is a major change in intended use that needs a new premarket notification (21 CFR 807.81). FDA also cited missing quality system procedures under 21 CFR Part 820 and no written procedure for evaluating complaints under 21 CFR 803.17.
What to do: if your gym or recovery studio uses or sells a muscle stimulator, describe it only by its cleared uses in your menu, your staff scripts and your social posts. Gyms and fitness.
Source: FDA warning letter 731847
5. FDA finalizes its Q&A on mandatory cosmetics recalls
On October 23, 2026, FDA published final guidance, Questions and Answers Regarding Mandatory Cosmetics Recalls (FR Doc. 2026-21679, 91 FR 66851). It finalizes the draft guidance published December 18, 2025 and describes FDA’s current thinking on the criteria, process and expectations for mandatory cosmetic recalls. The notice lists no comment deadline.
What to do: if your med spa retails skincare or cosmetics, keep lot numbers and supplier recall contacts for every product on your shelf, so you can pull one the day a notice arrives. Med spas.
Source: Federal Register 2026-21679
What this means for you
Four of this week’s five items come down to a document you should already be able to produce: an approved application or license for what you infuse, a current state license behind every DEA registration, a cleared indication for every device claim. FDA wrote to the Medical Director of an IV company, so the person who signs your protocols is part of the record. This week, list every product on your menu and write next to each one the approval, license or clearance that covers it. If any line stays blank, book a call and we will review it with you.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.